Maria, 68, was told she had chronic lymphocytic leukemia. She didn’t feel sick, but her blood counts were off. The doctor listed treatment options—some lasted six months, others were daily pills. She wanted the best shot at staying healthy—without unnecessary side effects.
She’s not alone. CLL is the most common type of leukemia in adults in the U.S. It grows slowly, but over time, it weakens the immune system. For years, treatment meant chemo plus antibodies. Now, targeted drugs have changed the game. But a big question remains: Is a single daily pill as good as—or even better than—taking two powerful drugs together for a set time?
Most patients want the simplest, safest path. Yet many doctors still choose combo therapies, thinking more drugs mean better results. These regimens can work well, but they often come with fatigue, infections, and hospital visits.
But here’s the twist: New data suggest one drug—zanubrutinib—might do more than a two-drug combo.
Think of CLL cells like rogue factory workers. They multiply nonstop because a broken switch keeps them turned on. BTK inhibitors like zanubrutinib and acalabrutinib are like repair tools. They fix the switch, telling the cells to stop growing. Venetoclax is a different tool—it forces the bad cells to self-destruct. Combining them seemed like a smart plan.
But what if one repair tool is just that much better?
Zanubrutinib is designed to stay locked onto the faulty switch longer and more precisely. It’s like a magnet with a tighter grip. This could mean stronger control with just one drug—no need to add another.
The data come from two large trials. In SEQUOIA, patients took zanubrutinib alone. In AMPLIFY, others took acalabrutinib plus venetoclax—with or without an antibody. The patients were similar: newly diagnosed, no high-risk genetic flaws like del(17p). But SEQUOIA also included people who couldn’t handle chemo, making them a bit sicker on average.
Even with that, zanubrutinib came out ahead.
After three years, 84.3% of patients on zanubrutinib had no disease progression. In the combo group, it was 78.9%. That’s a meaningful gap. When researchers focused only on patients healthy enough for standard chemo, zanubrutinib’s edge grew—89.2% remained progression-free.
A deeper analysis adjusted for age, stage, and other risks. It found patients on zanubrutinib were 55% less likely to see their disease worsen. One study even reported a 74% lower risk when accounting for age.
That’s not the full story.
These results are not from a head-to-head trial. Instead, scientists used a statistical method to match patients across studies. This is smart, but not perfect. It can’t capture every difference between clinics, doctors, or how symptoms were tracked.
Still, experts say the findings are compelling. They fit with what we’re learning: not all BTK inhibitors are the same. Zanubrutinib’s design may give it a durability edge.
For patients, this could mean a future where effective treatment is simpler. No IVs. No fixed end date. Just one pill, taken daily, that keeps leukemia in check.
This doesn't mean this treatment is available yet.
Zanubrutinib is approved for some CLL cases, but not everyone has access. And combo therapy remains a standard choice, especially for younger, healthier patients.
The analysis has limits. It didn’t compare side effects in detail. It didn’t track quality of life. And it didn’t include patients with the highest-risk mutations in both groups equally.
Still, the trend is clear: monotherapy isn’t falling behind. It might be pulling ahead.
What happens next? A direct trial comparing zanubrutinib alone to acalabrutinib-venetoclax is likely needed before guidelines change. That could take years. In the meantime, doctors may start rethinking whether every patient needs a combo—or if one well-chosen drug is enough.
For people like Maria, that conversation could mean less worry, fewer pills, and more time living well.
